NCT04821219View on ClinicalTrials.gov

Personalized Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 1, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Pancreas Adenocarcinoma
Interventions
OTHER

Treatment prediction PDT platform

PDT will be generated and response to various chemotherapies and radiation will be investigated. Actionable targets will be identified and response to the target drug will be assessed and compared to the conventional treatment options.

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04821219 - Personalized Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids | Biotech Hunter | Biotech Hunter